PT - JOURNAL ARTICLE AU - Eric Brum AU - Senjuti Saha AU - Ayesha Sania AU - Arif Mohammad Tanmoy AU - Yogesh Hooda AU - Afroza Akter Tanni AU - Sharmistha Goswami AU - Syed Muktadir Al Sium AU - Mohammad Saiful Islam Sajib AU - Roly Malaker AU - Shuborno Islam AU - Nikkon Sarker AU - Samir K Saha AU - Shayan Chowdhury AU - Yacob Haddou AU - Elaine Ferguson AU - Mikolaj Kundegorski AU - Nabila Purno AU - Motahara Tasneem AU - Shams El Arifeen AU - AMS Alamgir AU - Anir Chowdhury AU - Katie Hampson TI - Surging COVID-19 in Bangladesh driven by B.1.351 variant AID - 10.1101/2021.04.27.21255706 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.27.21255706 4099 - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21255706.short 4100 - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21255706.full AB - A dramatic resurgence of COVID-19 cases and deaths in Bangladesh in March 2021 coincided with the SARS-CoV-2 B.1.351 (501Y.V2) variant of concern rapidly becoming the dominant circulating variant. Concurrently, increasing numbers of reinfections have been detected and the effective Reproductive number, Rt, has doubled, despite high levels of prior infection in Dhaka city. These data support the prediction that acquired immunity from past infection provides reduced protection against B.1.351, and highlights the major public health concern posed by immune escape variants, especially in populations where vaccination coverage remains low.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThe Bill and Melinda Gates Foundation funded work by FAO (INV-022851) and CHRF (INV-016932, INV-023821) and UoG reports funding from Wellcome (095787/Z/11/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDate and code to reproduce the study are available from our Github repository. https://github.com/boydorr/BGD_Covid-19.